CryoSave has maintained without compromise the high-quality processing and storage services and has handed over its whole business.
Switzerland – 19 September 2019
CryoSave has since its establishment in 2000, ensured the best security for its clients and has a proven track record of professionalism and expertise in the field of stem cells banking, recognized by the medical community.
CryoSave is one of the largest and longest operating stem cell banks in Europe, having stored more than 330.000 umbilical cord blood samples and tissues over the past 20 years.
All laboratory protocols have been established in compliance with the international guidelines and granted with authorization for autologous and allogeneic transplantations.
On the 22th of February 2019, CryoSave AG (Switzerland) and PBKM (Poland) have concluded a Backup and Storage Agreement concerning the storage of all CryoSave stem cells samples by PBKM in its state of the art and fully secured laboratories in Warsaw, Poland.
We quote PBKM website:
Containers with the biological material of most of CryoSave‘s customers have been safely transported upon the order of CryoSave to the PBKM FamiCord Group laboratory in Poland. CryoSave decided to entrust this service to PBKM Famicord due to the fact that PBKM Famicord is regarded as the most reliable bank among European banks, their storage standards and many years of very good financial standing (https://famicord.eu/contact-with-famicord).
Following, on the 7th of March 2019, CryoSave advised in good faith the Swiss Authorities of its intention to move the samples to Poland and the 2nd of July 2019 the OFSP and Swissmedic have been informed that no more cord blood samples were stored in Switzerland and that CryoSave laboratory in Geneva has stopped its activities. Consequently, it was no need and justification to maintain the federal authorization to import, export, process and store umbilical cord blood stem cells.
In the meantime, more than 500’000 email communications have been sent to our customers.
The 1st of July 2019, we issued a multi-language Press Release on Reuters and on our website to confirm the safety of all the samples stored in Poland and therefore reassure our clients that the umbilical cord blood stem cells are the patient’s property and remain safely stored under CryoSave’s supervision.
Finally, on the 27th of August Esperite, CryoSave and Myrisoph Capital have concluded a strategic Agreement related to Cryo-Save’s stem cell cryopreservation business. Myrisoph becomes the exclusive global licensee of the CryoSave brand.
We quote Myrisoph:
We are confident that our management team will turn CryoSave into a global leader by implementing our best practices. Our priority will be to ensure that existing and future clients will be fully satisfied commented Hassan Alhassani, the President of Myrisoph Capital Inc.
CryoSave has always strived to act in its client’s best interests and best practices.
The whole stem cell activity has been transfered to Myrisoph, a reputable and experienced company which in collaboration with PBKM will ensure the best continuity for the customers.
To contact us: ir@esperite.com or visit the websites at www.esperite.com
Attachment
